Document is current

Article History

Received: 11 August 2023

Accepted: 7 July 2024

First Online: 24 July 2024

Declarations

:

: This manuscript reports the results from a market research survey, which was carried out in accordance with guidelines set by the European Pharmaceutical Market Research Association (EphMRA) and the British Healthcare Business Intelligence Association (BHBIA). Approval from a research ethics committee is not required to undertake market research, as stated by the EphMRA (EphMRA 2022 Code of Conduct (). Market Research, Ethics Approval and Non-Interventional Research, Sect. 1.3) and BHBIA (Legal and Ethical Guidelines for Healthcare Market Research: Your Essential Guide (). Some Important Definitions, Sect. 3). This is because market research falls outside the remit of governance arrangements for research ethics committees, as stated by the UK National Health Service Research Authority (Governance arrangements for research ethics committees: 2020 edition (UK National Health Service Research Authority ). Exceptions, Sect. 2.3.15). Due to this, no approval (or waiver) from a research ethics committee was sought.All respondents provided their written informed consent to participate in this study during the first section of the online questionnaire. Respondents who did not provide their consent were not able to proceed with completing the questionnaire. In line with British Healthcare Business Intelligence Association guidance, respondents were informed that the survey was being carried out by Cello Health (London, UK) on behalf of a client in the pharmaceutical industry. Personal details of respondents were not shared with GW Pharmaceuticals (part of Jazz Pharmaceuticals, Cambridge, UK) and data was analysed anonymously.

: Not applicable.

: The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: ER has received speaker fees or fundings or has participated in advisory boards for Angelini, Arvelle Therapeutics, Eisai, Kolfarma, Pfizer, GW Pharmaceuticals, UCB, Lundbeck. PMA has received speaker fees from UCB, Eisai, Bial, Cyberonics, Neuraxpharn, Kern Pharma and Pfizer. PF has received speaker’s fees and honoraria for advisory boards from Almirall, Bayer, Biogen Idec, BMS/Celgene, Coloplast, Hexal, Janssen-Cilag, Genzyme, Novartis, Merck-Serono, Roche, Sanofi Aventis, Stadapharm and Teva. CL has received speaker fees and honoraria for advisory boards for Eisai, UCB Pharma, Bial and GW Pharmaceuticals. DM is an employee of Cello Health Insight (London UK). Cello Health Insight was funded by GW Pharmaceuticals (part of Jazz Pharmaceuticals) to conduct the market research on which this paper is based. CH is a full-time employee of GW Pharmaceuticals (part of Jazz Pharmaceuticals). MB was a full-time employee of GW Pharmaceuticals (part of Jazz Pharmaceuticals) when the study was conducted. ET has provided paid consultancy to Arvelle, Argenx, Angelini, Clexio, UCB, Eisai, Epilog, Bial, Medtronic, Ever-pharma, Biogen, Takeda, Jazz, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals and Marinus. He has received research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer and UCB. He has received speaker honoraria from Arvelle, GSK, GW Pharmaceuticals, Böhringer, Ingelheim, Eisai, Bial, Everpharma, UCB, Liva-Nova, Newbridge, Hikma, Novartis and Sanofi. He has received competitive research grants from Austrian Science Fund (FWF) and Österreichische Nationalbank, European Union, and he is the CEO of Neuroconsult GmbH.